Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126477621 | 12647762 | 1 | I | 20160804 | 20160812 | 20160812 | EXP | IN-MYLANLABS-2016M1032880 | MYLAN | DAS S, RAMASAMY A, DE S, MONDAL S. AN UNUSUAL CASE OF GLIPIZIDE-INDUCED PROXIMAL MYOPATHY. J-PHARMACOL-PHARMACOTHER 2016;7(2):99-101. | 0.00 | Y | 0.00000 | 20160812 | OT | IN | IN |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126477621 | 12647762 | 1 | PS | GLIPIZIDE. | GLIPIZIDE | 1 | Oral | 5 MG/DAY, AFTER 2MO THE DOSE WAS INCREASED TO 10 MG/DAY | Y | Y | 74226 | ||||||||
126477621 | 12647762 | 2 | SS | GLIPIZIDE. | GLIPIZIDE | 1 | Oral | 10 MG, QD | Y | Y | 74226 | 10 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126477621 | 12647762 | 1 | Type 2 diabetes mellitus |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126477621 | 12647762 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126477621 | 12647762 | Fatigue | |
126477621 | 12647762 | Malaise | |
126477621 | 12647762 | Myopathy | Myopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |